Impairment of Bilirubin Clearance and Intestinal Interleukin-6 Expression in Bile Duct-Ligated Vitamin D Receptor Null Mice

Michiyasu Ishizawa¹, Michitaka Ogura¹*, Shigeaki Kato², Makoto Makishima¹*
¹ Division of Biochemistry, Department of Biomedical Sciences, Nihon University School of Medicine, Tokyo, Japan, ² Institute of Molecular and Cellular Biosciences, The University of Tokyo, Tokyo, Japan

Abstract

The vitamin D receptor (VDR) mediates the physiological and pharmacological actions of 1α,25-dihydroxyvitamin D3 in bone and calcium metabolism, cellular growth and differentiation, and immunity. VDR also responds to secondary bile acids and belongs to the NR1I subfamily of the nuclear receptor superfamily, which regulates expression of xenobiotic metabolism genes. When compared to knockout mouse investigations of the other NR1I nuclear receptors, pregnane X receptor and constitutive androstane receptor, an understanding of the role of VDR in xenobiotic metabolism remains limited. We examined the effect of VDR deletion in a mouse model of cholestasis. We performed bile duct ligation (BDL) on VDR-null mice and compared blood biochemistry, mRNA expression of genes involved in bile acid and bilirubin metabolism, cytokine production, and expression of inflammatory regulators with those of wild-type mice. VDR-null mice had elevated plasma conjugated bilirubin levels three days after BDL compared with wild-type mice. Urine bilirubin levels and renal mRNA and/or protein expression of multidrug resistance-associated proteins 2 and 4 were decreased in VDR-null mice, suggesting impaired excretion of conjugated bilirubin into urine. While VDR-null kidney showed mRNA expression of interleukin-6 (IL-6 after BDL and VDR-null macrophages had higher IL-6 protein levels after lipopolysaccharide stimulation, the induction of intestinal Il6 mRNA expression and plasma IL-6 protein levels after BDL was impaired in VDR-null mice. Immunoblotting analysis showed that expression of an immune regulator, Il6Ra, was elevated in the jejunum of VDR-null mice, a possible mechanism for the attenuated induction of Il6 expression in the intestine after BDL. Increased expression of Il6Ra may be a consequence of compensatory mechanisms for VDR deletion. These results reveal a role of VDR in bilirubin clearance during cholestasis. VDR is also suggested to contribute to tissue-selective immune regulation.

Introduction

The vitamin D receptor (VDR; NR1I1) is a nuclear receptor that mediates the physiological function of the active form of vitamin D, 1α,25-dihydroxyvitamin D3 [1,25(OH)2D3], in numerous processes including bone and calcium metabolism, cellular growth and differentiation, immunity, and cardiovascular function [1,2]. Upon ligand binding, VDR undergoes conformational changes that result in dynamic interaction with the heterodimer partner retinoid X receptor (RXR; NR2B) and exchange of cofactor complexes [3]. The VDR-RXR heterodimer binds preferentially to a vitamin D response element that consists of a two hexanucleotide (AGGTCA or a related sequence) direct repeat motif separated by three nucleotides, which has been identified in the regulatory regions of many target genes, including cytochrome P450 (CYP) genes. An everted repeat of the hexanucleotide motif separated by six, seven, eight or nine nucleotides has also been identified as vitamin D response elements in genes such as CYP3A4 [2,5]. VDR also acts as a receptor for secondary bile acids, such as lithocholic acid and 3-ketocholestanic acid, and induces their catabolism via induction of CYP3A enzymes [6,7]. While CYP24A1 is involved in the catabolism of 25-hydroxyvitamin D3 and 1,25(OH)2D3 [8], CYP3A4 catalyzes the metabolic conversion of a wide variety of xenobiotics and endogenous substrates, including 1,25(OH)2D3 [9,10]. VDR activation has been shown to induce the expression of other enzymes and transporters involved in xenobiotic metabolism, such as multidrug resistance-associated protein 2 (MRP2; gene symbol, Abcc2), MRP3 (Abcc3), MRP4 (Abcc4) and sulfotransferase 2A1 [11–16]. VDR belongs to the NR1I1 nuclear receptor subfamily along with pregnane X receptor (PXR; NR1I2) and constitutive androstane receptor (CAR; NR1I3), both of which play a role in the regulation of xenobiotic metabolism [17]. Compared with PXR and CAR, however, our understanding of the role of VDR in xenobiotic metabolism remains limited.
Cholestasis is associated with hepatic and systemic accumulation of biliary compounds, such as bile acids and bilirubin, and subsequent tissue damage [18]. Decreased secretion of bile acids into the intestine induces proliferation and translocation of intestinal bacteria, leading to endotoxemia and sepsis [19].

Endotoxin and proinflammatory cytokines can cause endotoxin-induced cholestasis and exacerbate liver injury. The bile acid-sensing nuclear receptors farnesoid X receptor (FXR; NR1H4) and PXR have been investigated in the rodent bile-duct ligation (BDL) model of cholestasis. FXR activation by synthetic ligands

Figure 1. Effect of VDR deletion on plasma transaminases, total bile acids and bilirubin levels. (A) AST and ALT. (B) Total bile acids. (C) Total and conjugated bilirubin levels. Wild-type mice (WT) and VDR-null mice (VDR-KO) (n = 4–8 per group) were subjected to sham operation or BDL and plasma samples were collected 3 days and 7 days after surgery. (D) Urine bilirubin levels. Twenty-four-hour urine samples were collected 1 day, 2 days and 3 days after surgery and subjected to total bilirubin measurement. The values represent means ± S.D. *p < 0.05; **p < 0.01; ***p < 0.001. n.s., not significant.

doi:10.1371/journal.pone.0051664.g001
Role of Vitamin D Receptor in Cholestasis

Peritoneal macrophages

Peritoneal macrophages were obtained from mice treated with 3% thioglycollate intraperitoneally for 4 days [28]. Cells were cultured in RPMI 1640 medium containing 10% fetal bovine serum, 100 units/ml penicillin and 100 mg/ml streptomycin for 24 hours and then treated with or without 10 ng/ml lipopolysaccharide (LPS) for 12 hours.

Reverse transcription and real-time quantitative polymerase chain reaction

Total RNAs from samples were prepared by the acid guanidinium thiocyanate-phenol/chloroform method [14]. cDNAs were synthesized using the ImProm-II Reverse Transcription system (Promega Corporation, Madison, WI). Intron-spanning primers were as follows: Abcc3 (GenBank accession no. NM_029600), 5'-GCC AAC TTC CTC CGA AAC TA-3' and 5'- GTT GGG AGC CTC GTA GAT GG-3'; Ugt1a1 (GenBank accession no. NM_201645), 5'- TCT GAG CCC TGC ATC TAT CT-3' and 5'- AGA GGC GTT GAC ATA GGC TT-3'; Socl1 (GenBank accession no. NM_009896), 5'- GTG GTT GTG GTG GGT GAG GAT AT-3' and 5'- CCC AGA AGC AAC CAG CTT GCA CA-3'; Socl3 (GenBank accession no. NM_007707), 5'- TTG TGC GAA GAC TGT CAA CG-3' and 5'- GAG GAT CAT GAT CCT CGA GG-3'. Other primer sequences have reported previously [14,27,29]. The mRNA values were normalized to the amount of glyceraldehyde-3-phosphate dehydrogenase mRNA.

Immunoblotting

For MRP4 expression, membrane fractions from the kidney were prepared as reported previously [30]. For 1kBz expression, tissue samples form the jejunum and kidney were homogenized in buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate, 1% NP40) containing a protease inhibitor cocktail, and centrifuged to remove debris. Western blot analysis was performed using anti-MRP2 antibody (Santa Cruz Biotechnology, Santa Cruz, CA), an anti-MRP4 antibody (Santa Cruz Biotechnology), an anti-lamin B antibody (Santa Cruz Biotechnology), an anti-lamin B antibody (Santa Cruz Biotechnology), an anti-lamin A antibody (Sigma-Aldrich, St. Louis, MO), visualized with an alkaline phosphatase conjugate substrate system or an enhanced chemiluminescence detection system [15,31,32].

Statistical analysis

All values are shown as mean ± S.D. The unpaired two-group Student’s t test was performed to assess significant differences.

Results

VDR deletion increases plasma conjugated bilirubin levels in BDL mice

To examine the effect of VDR deletion on cholestasis, we performed BDL and sham surgery on wild-type mice and VDR-null mice. Plasma AST and ALT levels increased drastically 3 days after BDL, while sham surgery had no effect (Fig. 1A). There was no significant difference in AST and ALT levels between wild-type mice and VDR-null mice (Fig. 1A). Increased total bile acid levels at both day 3 and day 7 were not changed by VDR deletion (Fig. 1B). Interestingly, plasma total bilirubin levels 3 days after BDL were significantly elevated in VDR-null mice (Fig. 1B). VDR-null mice had lower concentrations of urine bilirubin than wild-type mice at day 2 after BDL, and a similar pattern was observed at day 3 although it did not reach statistical significance (Fig. 1D). There was no significant difference in plasma total bilirubin levels 7 days after BDL between wild-type mice and VDR-null mice (Fig. 1C), a finding between wild-type mice and VDR-null mice (Fig. 1A). Increased total bile acid levels at both day 3 and day 7 were not changed by VDR deletion (Fig. 1B). Interestingly, plasma total bilirubin levels 3 days after BDL were significantly elevated in VDR-null mice (Fig. 1B). VDR-null mice had lower concentrations of urine bilirubin than wild-type mice at day 2 after BDL, and a similar pattern was observed at day 3 although it did not reach statistical significance (Fig. 1D). There was no significant difference in plasma total bilirubin levels 7 days after BDL between wild-type mice and VDR-null mice (Fig. 1C), a finding...
that may be due to saturation of plasma bilirubin levels. Accumulation of conjugated bilirubin contributed to increased plasma bilirubin levels in VDR-null mice treated with BDL (Fig. 1C). Thus, VDR deletion decreases the urinary clearance of conjugated bilirubin from blood in BDL mice.

We next examined the mRNA expression of genes involved in metabolism and transport of bile acids and bilirubin in the liver of mice 7 days after sham or BDL surgery. Cyp7a1, Cyp8b1 and Cyp27a1 encode bile acid synthetic enzymes [33]. Although previous reports have shown that BDL increases Cyp7a1 expression [29,34,35], there was no difference in Cyp7a1 expression among sham-operated wild-type, BDL wild-type, sham-operated VDR-null and BDL VDR-null mice (Fig. 2A). As reported previously [14,24], BDL decreased Cyp8b1 expression in wild-type mice. The decrease in Cyp8b1 mRNA levels in VDR-null mice subjected to BDL was similar to that in wild-type mice (Fig. 2A). Cyp27a1 expression was slightly decreased by BDL in wild-type mice and VDR deletion did not affect Cyp27a1 expression (Fig. 2A). Cyp3a11 is a target gene of VDR, PXR and CAR [6,36,37], and BDL has been shown to increase Cyp3a11 expression [29,38,39]. In our experiments, BDL tended to increase Cyp3a11 expression but this effect was not significant due to large variation (Fig. 2A). BDL did not change Cyp3a11 mRNA levels in VDR-null mice. A CAR target gene, Ugt1a1, encodes a bilirubin-conjugating enzyme [25]. Ugt1a1 expression was decreased to a similar extent in the liver 7 days after BDL in both wild-type and VDR-null mice (Fig. 2A).

Na+/taurocholate cotransporting polypeptide (NTCP; encoded by the Slc10a1 gene) is involved in bile acid uptake at the basolateral membrane of hepatocytes [18]. OATP1A1 (encoded by the Slco1a1 gene), OATP1A4 (encoded by the Slco1a4 gene) and OATP1B2 (encoded by the Slco1b2 gene) are basolateral transporters for the uptake of bile acids and bilirubin in the liver [18,40]. As reported previously [14,24,41], BDL decreased Slc10a1 expression in wild-type mice (Fig. 2B). BDL also tended to decrease Slco1a1 and Slco1b2 expression but these differences were not significant, while a significant decrease in Slco1b2 expression

Figure 2. Hepatic mRNA expression of genes involved in bile acid and bilirubin metabolism. mRNA expression of enzymes (A), uptake transporters (B) and efflux transporters (C) were examined. Total RNAs were prepared from the liver of wild-type mice (WT) and VDR-null mice (VDR-KO) 7 days after sham operation or BDL. The values represent means ± S.D. *p<0.05; **p<0.01; ***p<0.001.

doi:10.1371/journal.pone.0051664.g002
was observed in BDL VDR-null mice compared with sham-operated VDR-null mice (Fig. 2B). Slco1a4 mRNA levels were not changed after BDL. VDR deletion did not affect expression of these uptake transporters in the liver of sham-operated and BDL mice (Fig. 2B).

BSEP (encoded by the Abcb11 gene) and MRP2 (encoded by the Abcc2 gene) are localized in the canalicular membrane of hepatocytes and excrete bile acids into bile, while MRP3 (encoded by the Abcc3 gene), MRP4 (encoded by the Abcc4 gene), organic solute transporter (OST) α (encoded by the Osta gene), and OSTβ (encoded by the Ostb2 gene) are found at the hepatocyte basolateral membrane and play a role in the alternative excretion of bile acids into the systemic circulation [18]. There was no difference in Abcb11 expression in sham-operated wild-type, BDL wild-type, sham-operated VDR-null and BDL VDR-null mice (Fig. 2C). BDL tended to decrease Abcc2 and Abcc3 expression in wild-type mice but not in VDR-null mice (Fig. 2C). BDL increased Abcc4 expression in VDR-null mice but this effect was not significant in wild-type mice (Fig. 2C). BDL increased Ostb expression in both wild-type and VDR-null mice (Fig. 2C). There was no significant difference in the expression of these genes in wild-type and VDR-null mice.

VDR deletion decreases MRP2 and MRP4 expression in the kidney of BDL mice

Hepatic MRP2 and MRP3 have been reported to be involved in the transport of conjugated bilirubin in mice [42–45]. In the kidney, MRP2 and MRP4 are expressed on the apical membrane
in proximal tubule cells, while MRP3 localizes to the basolateral membrane of distal convoluted tubules [46]. We first examined mRNA expression of renal MRP transporters. There was no difference in *Abcc2* expression in sham-operated wild-type, BDL wild-type, sham-operated VDR-null and BDL VDR-null mice (Fig. 3A). Expression of *Abcc3* and *Abcc4* tended to decrease in VDR-null mice compared with wild-type mice following sham operation. Expression levels of these transporters were significantly lower in VDR-null mice with BDL than in sham-operated, wild-type mice (Fig. 3A). The heterodimeric bile acid transporter genes, *Osta* and *Ostb*, were increased by BDL to similar levels in wild-type and VDR-null mice (Fig. 3A). We confirmed the loss of *Vdr* mRNA expression in the kidney of VDR-null mice (Fig. 3A). Next, we examined protein expression of the renal apical efflux transporters MRP2 and MRP4. MRP2 and MRP4 protein levels were elevated by BDL in wild-type mice (Fig. 3B). Interestingly, protein expression of MRP2 and MRP4 was not changed after BDL in VDR-null mice (Fig. 3B). Thus, VDR deletion impairs the renal expression of MRP2, MRP3 and MRP4 at the mRNA and/or protein levels.

VDR deletion changes intestinal cytokine mRNA expression after BDL

Since we have previously reported that pharmacological VDR activation represses inflammatory cytokine expression in BDL mice [14], we examined mRNA expression of inflammatory cytokines in the liver and intestine. In contrast to pharmacological VDR activation, VDR deletion did not affect BDL-induced changes in hepatic expression of interleukin-1β (gene symbol, *Il1b*), interleukin-6 (IL-6; gene symbol, *Il6*) and tumor necrosis factor (gene symbol, *Tnf*) (Fig. 4A), suggesting that VDR activity regulated by endogenous ligands is not involved in hepatic cytokine mRNA expression after BDL. Interestingly, BDL decreased jejunal *Il1b* expression in wild-type mice but not in VDR-null mice (Fig. 4B). Duodenal and ileal *Il1b* expression tended to decrease after BDL in wild-type mice and did not change in VDR-null mice. Similar to *Il1b*, jejunal *Tnf* expression decreased after BDL in wild-type mice but not in VDR-null mice (Fig. 4B). Duodenal *Tnf* tended to decrease after BDL in both wild-type mice and VDR-null mice. Ileal *Tnf* decreased after BDL in VDR-null mice but not to a significant degree in wild-type mice.

**Figure 4.** mRNA expression of inflammatory cytokines in the liver (A) and intestine (B). Total RNAs were prepared from the liver of wild-type mice (WT) and VDR-null mice (VDR-KO) 3 days and 7 days after sham operation or BDL. The values represent means ± S.D. *p<0.05; **p<0.01. doi:10.1371/journal.pone.0051664.g004
VDR deletion is associated with increased Il6 protein levels in the intestine

VDR null mice have increased serum IL-6 levels and VDR deletion elevates nuclear factor (NF)-κB activity in intestinal epithelia and mouse embryonic fibroblasts (MEFs) [47]. In agreement with these findings, VDR-null peritoneal macrophages showed elevated IL-6 secretion (Fig. 5C). However, intestinal Il6 mRNA expression and plasma IL-6 levels were less increased after BDL in VDR-null mice compared with wild-type mice (Fig. 4B and 5A). We speculated that while VDR primarily regulates inflammatory responses by suppressing NF-κB activity, VDR deletion may induce compensatory immunoregulatory mechanisms in the intestine. Since suppressor of cytokine signaling (SOCS) 1 and SOCS3 have been reported to inhibit LPS-induced IL-6 production [48,49], we examined the expression of Socs1 and Socs3 in the intestine. There was no difference in Socs1 expression in sham-operated wild-type, BDL wild-type, sham-operated VDR-null and BDL VDR-null mice, although BDL tended to decrease Socs1 expression in wild-type mice (Fig. 6A). BDL tended to increase duodenal, jejunal and ileal Socs3 expression. Interestingly, duodenal Socs3 mRNA levels in VDR-null mice were lower than in wild-type mice (Fig. 6A), a pattern similar to that observed for Il6 expression (Fig. 4B). Jejunal and ileal Socs3 expression tended to increase after BDL in VDR-null mice. Decreased Il6 induction in the intestine of VDR-null mice with BDL cannot be explained by the expression of Socs1 or Socs3. Intestinal Socs3 expression may be regulated by other cytokines such as IL-6 [50].

NF-κB induces mouse Il6 transcription [51], and 1α,25-dihydroxyvitamin D₃ binds to NF-κB and represses its transactivation activity [52]. We examined 1α,25-dihydroxyvitamin D₃ expression in jejunal and kidney by immunoblotting. Interestingly, jejunal 1α,25-dihydroxyvitamin D₃ protein levels were higher in VDR-null mice than wild-type mice, while its expression was similar in the kidney of VDR-null mice and wild-type mice (Fig. 6B). Thus, higher 1α,25-dihydroxyvitamin D₃ protein levels are associated with reduced Il6 induction in the jejunum of VDR-null mice.

**Discussion**

In this study, we examined the effects of VDR deletion in a mouse model of cholestasis and found that VDR-null mice show increased plasma bilirubin levels and reduced intestinal Il6 induction after BDL compared to wild-type mice. Under physiological conditions, conjugated bile acids and conjugated bilirubin are secreted from the canalicular membrane of hepatocytes into bile. Under cholestatic conditions, however, these compounds are effluxed from the basolateral membrane of hepatocytes to the blood circulation and are then excreted into the urine via renal transporters, a major alternative elimination route [18]. VDR-null mice accumulated higher levels of conjugated bilirubin in the plasma than wild-type mice (Fig. 1). We examined the effect of 1α,25-dihydroxyvitamin D₃ treatment on hyperbilirubinemia induced by intravenous bilirubin infusion in wild-type mice and found that VDR activation did not increase the rate of clearance of exogenous bilirubin (unpublished data). Injected bilirubin is glucuronidated in hepatocytes and excreted into bile. Expression of Ugt1a1 was similar between wild-type mice and VDR-null mice (Fig. 2). Thus, VDR deletion disrupts the clearance of conjugated bilirubin from blood rather than bilirubin conjugation in BDL mice.
Role of Vitamin D Receptor in Cholestasis

A

**Socs1**

| Tissue   | Condition | WT | VDR-KO |
|----------|-----------|----|--------|
| Duodenum | BDL       | 1  | 1      |
|          | +         | 1  | 1      |
| Jejunum  | BDL       | 1  | 1      |
|          | +         | 1  | 1      |
| Ileum    | BDL       | 1  | 1      |
|          | +         | 1  | 1      |

**Socs3**

| Tissue   | Condition | WT | VDR-KO |
|----------|-----------|----|--------|
| Duodenum | BDL       | 1  | 1      |
|          | +         | 1  | 1      |
| Jejunum  | BDL       | 1  | 1      |
|          | +         | 1  | 1      |
| Ileum    | BDL       | 1  | 1      |
|          | +         | 1  | 1      |

B

**Jejunum**

- **IkBα/β-Actin**
  - WT: 1
  - VDR-KO: *2*

**Kidney**

- **IkBα/β-Actin**
  - WT: 1
  - VDR-KO: *2*
MRP2, MRP3, and MRP4 are involved in transport of bile acids and/or bilirubin in the liver and kidney [18,46]. MRP2 is localized at the canicular membrane of hepatocytes and MRP2-null mice show increased serum conjugated bilirubin [42,43], indicating that MRP2 plays a role in biliary excretion of conjugated bilirubin. MRP3 and MRP4 are expressed at the basolateral hepatocyte membrane [46]. BDL results in reduced accumulation of serum conjugated bilirubin in MRP3-null mice [44,45]. MRP4-null mice have reduced serum bile acids but similar conjugated bilirubin levels after BDL [53]. MRP3, which is upregulated in MRP4-null mice, is insufficient for basolateral bile acid secretion [53], but may adequately compensate for bilirubin excretion. As reported previously [14,29,35,54], BDL did not increase hepatic Abcc2 mRNA expression in wild-type mice (Fig. 2). Hepatic Abcc3 and Abcc4 mRNA have been reported to be upregulated after BDL [29,35,54]. In our results, BDL tended to increase Abcc4 but not Abcc3 expression in the liver of wild-type mice (Fig. 2). Potential confounding factors of BDL, such as secondary inflammation, may influence Abcc3 expression [55]. VDR deletion had a modest or no effect on the regulation of hepatic genes involved in the metabolism of bile acids and bilirubin during cholestasis (Fig. 2).

VDR ligand treatment does not induce hepatocyte target gene expression due to the low expression of VDR in liver [56,57]. While VDR activation does not alter bile acid accumulation in BDL mice [14], it enhances urinary excretion of bile acids by increasing the expression of bile acid transporter genes in mice fed chow supplemented with chenodeoxycholic acid [15]. These findings suggest that an increase in plasma conjugated bilirubin in VDR-null mice with BDL is due to impaired expression of renal transporters of bilirubin.

In the kidney, MRP2 and MRP4 are localized to the apical tubular membrane, while MRP3 is expressed in the basolateral membrane of the distal convoluted tubule [18,46]. We observed reduced MRP2 protein levels and MRP4 mRNA and protein levels in the kidney of VDR-null mice (Fig. 3), consistent with our previous reports that show that pharmacological VDR activation increases mRNA and/or protein expression of MRP2 and MRP4 [14,15]. There were some discrepancies between mRNA and protein levels of MRP2 and MRP4 (Fig. 3). 1,25(OH)2D3 treatment increases MRP2 and MRP4 protein levels without changing mRNA levels in the rat intestine [16]. 1,25(OH)2D3 also induces MRP2 and MRP4 protein expression with increasing ABCC2 mRNA levels but without affecting ABCC4 mRNA expression in human intestinal Caco-2 cells [13]. VDR activation may induce MRP2 and MRP4 expression through both transcriptional and posttranscriptional mechanisms. MRP2 plays a role in biliary excretion of conjugated bilirubin [42,43]. Although MRP4-null mice have serum bilirubin at the same levels as wild-type mice after BDL [53], a compensatory increase in MRP3 expression may mask the effect of MRP4 deficiency on bilirubin transport. MRP3-null mice exhibit BDL-induced liver damage at a similar extent to wild-type mice and have increased MRP4 expression [44,45]. Thus, hepatic MRP3 and MRP4 may have overlapping roles in basolateral eflux transport. In the kidney, in contrast to the basolateral transporter MRP3, the apical transporters MRP2 and MRP4 play a role in urinary excretion of endogenous and exogenous chemicals. Therefore, reduced induction of MRP2 and possibly MRP4 in the kidney could cause impaired urinary clearance of conjugated bilirubin in VDR-null mice, although an involvement of other VDR-dependent mechanisms cannot be ruled out. Thus, VDR may play a role in xenobiotic metabolism by regulating the expression of renal transporter genes.

In contrast to previous reports showing that BDL increases Cyp7a1 expression [29,34,35], BDL did not change Cyp7a1 expression (Fig. 2). BDL blocks bile flow into the intestine and decreases expression of fibroblast growth factor 15, a target gene of the bile acid receptor FXR [34]. Since secreted fibroblast growth factor 15 inhibits Cyp7a1 expression in the liver, BDL can increase Cyp7a1 expression [34]. On the other hand, accumulated bile acids in cholestasis induce activation of FXR and PXR in the liver [58]. FXR induces small heterodimer partner to inhibit Cyp7a1 expression and PXR also inhibits Cyp7a1 transcription. Furthermore, inflammatory cytokines inhibit Cyp7a1 expression [58]. In agreement with our results (Fig. 2), Cyp7a1 mRNA levels have been shown to be unchanged after BDL [14,54]. BDL has also been shown to decrease Cyp7a1 expression [59]. Thus, confounding factors associated with experimental conditions may affect Cyp7a1 expression.

BDL-induced Il6 expression in the intestine was diminished in VDR-null mice (Fig. 4). Plasma IL-6 levels after BDL were also lower in VDR-null mice when compared to wild-type mice (Fig. 5). These findings were unexpected because we have reported that 1α-hydroxyvitamin D3 treatment suppresses the increase in plasma IL-6 seen after BDL [14]. VDR-null mice have increased IL-6 production after Salmonella infection and VDR deletion is associated with elevated NF-κB in intestinal epithelia [47]. In Vdr−/− MEFs, the basal level of IkBα protein is markedly decreased when compared to Vdr+/− MEFs, leading to increased NF-κB transcriptional activity [60]. NF-κB is a major inducer of Il6 transcription [51,61–63]. VDR activation suppresses NF-κB activity by increasing IkBα levels in keratinocytes and macrophages [64,65], consistent with our previous report that shows that VDR activation decreases production of inflammatory cytokines, including IL-6 [14]. IL-6 production by peritoneal macrophages and renal Il6 mRNA expression were augmented in VDR-null mice (Fig. 5), supporting a proinflammatory state in VDR-null cells [47]. In contrast to peritoneal macrophages and kidney, the intestine of VDR-null mice exhibited less Il6 induction (Fig. 4). Plasma IL-6 protein levels exhibited a similar pattern to intestinal Il6 mRNA expression (Fig. 5), although we cannot rule out other tissue sources of IL-6 production. Interestingly, IkBα protein levels were higher in the jejunum of VDR-null mice than wild-type mice (Fig. 6). Vdr−/− MEFs have increased levels of IkBα mRNA, and decreased levels of IkBα protein, possibly due to increased protein degradation [66]. The VDR-null mice used in our experiments may maintain intestinal homeostasis by increasing IkBα protein levels. Through this mechanism, they may be resistant to Il6 induction after BDL when compared to wild-type mice.

VDR is activated by lithocholic acid and its derivatives [6,67,68]. While VDR deletion increased conjugated bilirubin, it did not affect total bile acids in the plasma (Fig. 1). Major bile acids that accumulate after BDL are cholic acid, β-muricholic acid and α-muricholic acid [14]. These bile acids fail to activate VDR both in cells and mouse tissues [6,14]. Although treatment of mice with 1α-hydroxyvitamin D3 induces expression of VDR target genes in

---

**Figure 6. VDR deletion increases intestinal Ikbα expression but not Socs1 or Socs3 mRNA expression.** (A) Socs1 and Socs3 mRNA expression in the intestine. Total RNAs were prepared from the liver of wild-type mice (WT) and VDR-null mice (VDR-KO) 3 days after sham operation or BDL. (B) Ikbα protein levels in the jejunum and kidney. Each lane was loaded with 50 μg (jejenum) or 100 μg (kidney) of whole tissue lysates. Band intensity was quantified with Image J 1.45 (n = 3–4). The values represent means ± S.D. *p<0.05.

doi:10.1371/journal.pone.0051664.g006
the liver, kidney and intestine, it is not enough to reduce accumulated bile acids [14]. In the context of BDL, VDR may fail to function as a regulator of bile acid metabolism. Lithocholic acid is a secondary bile acid generated by intestinal microflora and has minimal intestinal absorption [15,69], suggesting that intestinal microbiota contain lithocholic acid converting enzyme signaling from bacteria. Since VDR regulates intestinal immunity [47,70], it may mediate a host-bacterial signaling pathway through lithocholic acid or related compounds. Vitamin D signaling is also important in maintaining intestinal immunity [71]. VDR-null mice may develop an altered microflora-host immune, leading to differences in cytokine expression. Further investigation is needed to elucidate the mechanism of increased intestinal IkBα expression in VDR-null mice.

References

1. Nagul S, Na S, Rathnachalam R (2005) Nonalcoholic actions of vitamin D on liver. J Clin Invest 115: 2485–2497.
2. Choi M, Makishima M (2009) Therapeutic applications for novel non-hypercalcemic vitamin D receptor ligands. Expert Opin Ther Pat 19: 593–606.
3. Makishima M, Yamada S (2005) Targeting the vitamin D receptor: advances in the treatment of breast cancer. Expert Opin Ther Pat 15: 1135–1145.
4. Haasler MR, Whitley GK, Haasler CA, Hulch JC, Thompson PD, et al. (1998) The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 13: 325–349.
5. Thumneill KE, Briner C, Yasuda K, Thottassery J, Senn T, et al. (2001) Transcriptional control of intestinal cytochrome P-450 3A by 1,25-dihydroxyvitamin D$_3$. Mol Cell Biol 60: 1399–1406.
6. Xie W, Hashimah T, Shackley MC, Nelson WL, et al. (2006) Intestinal bile acid transporters and enzymes in the rat intestine and their role in bile acid disposition in mice. Drug Metab Diups 35: 2091–2095.
7. McCarthy TC, Li X, Sinal CJ (2005) Vitamin D receptor-dependent regulation of colon multidrug resistance-associated protein 3 gene expression by bile acids. J Biol Chem 280: 23232–23242.
8. Fan J, Liu S, Du Y, Morrison J, Shipman R, et al. (2006) Up-regulation of transporters and enzymes by the vitamin D receptor ligands, 1α,25-dihydroxyvitamin D$_3$ and vitamin D analogs, in the Caco-2 cell monolayer. J Biol Chem 281: 388–402.
9. Ogura M, Nishida S, Ishizawa M, Sakurai K, Shimizu M, et al. (2009) Vitamin D$_3$ modulates the expression of bile acid regulatory genes and represses inflammation in bile duct-ligated mice. J Pharmacol Exp Ther 328: 564–570.
10. Nishida S, Ozeki J, Makishima M (2009) Modulation of bile acid metabolism by 1α,25-dihydroxyvitamin D$_3$ administration in mice. Drug Metab Disups 37: 2037–2044.
11. Chow ECY, Sun H, Khan AA, Groothuis GMM, Pang KS (2010) Effects of 1α,25-dihydroxyvitamin D$_3$ on bile transporters and enzymes in the rat intestine and kidney in vivo. Biochim Biophys Disups 31: 91–108.
12. Gao J, Xie W (2010) Pregnan X receptor and constitutive androstane receptor at the crossroads of drug metabolism and energy metabolism. Drug Metab Diups 35: 2091–2095.
13. Zollner G, Marschall HU, Wagner M, Trauner M (2006) Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol Pharmacol 73: 231–251.
14. Inagaki T, Moschetta A, Lee Y-K, Peng L, Zhao G, et al. (2006) Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci USA 103: 3920–3925.
15. Liu Y, Bin J, Nemerick MJ, Dennis S, Luo J, et al. (2003) Hepatoprotection by the farnesoid X receptor agonist GW4694 in rat models of intra- and extracholestatic cholestasis. J Clin Invest 112: 1678–1687.
16. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, et al. (2006) Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 125: 711–744.
17. Stedman C, Liddle G, Coulter S, Sonoda J, Alvarez JE, et al. (2006) Benefit of farnesoid X receptor inhibition in obstructive cholestasis. Proc Natl Acad Sci USA 103: 11325–11326.
44. Belinsky MG, Dawson PA, Shchaveleva I, Bain LJ, Wang R, et al. (2005) Analysis of the in vivo functions of Mrp3. Mol Pharmacol 68: 160–168.

45. Klaassen CD, Aleksunes LM (2010) Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev 62: 1–96.

46. Wu SP, Liao AP, Xia YL, Li YC, Li JD, et al. (2010) Vitamin D receptor negatively regulates bacterial-stimulated NF-κB activity in intestine. Am J Physiol 177: 686–697.

47. Kimura A, Naka T, Muta T, Takeuchi O, Akira S, et al. (2005) Suppressor of cytokine signaling-1 selectively inhibits LPS-induced IL-6 production by regulating JAK-STAT. Proc Natl Acad Sci USA 102: 17089–17094.

48. Yan G, Gao J, Wu M, Zhang W, Jiang T, et al. (2010) Suppressor of cytokine signaling 3 inhibits LPS-induced IL-6 expression in osteoblasts by suppressing C/CAAT/enhancer-binding protein-β activity. J Biol Chem 285: 37227–37239.

49. Saccani S, Pantano S, Natoli G (2001) Two waves of nuclear factor κB recruitment to target promoters. J Exp Med 193: 1351–1359.

50. Starr R, Willson TA, Viney EM, Murray LJL, Rayner JR, et al. (1997) A family of cytokine-inducible inhibitors of signalling. Nature 387: 917–921.

51. Timonen A, Naka T, Murasawa S, Natoli G (2000) Two waves of nuclear factor κB activity. J Biol Chem 275: 17701–17709.

52. Hayden MS, Ghosh S (2012) NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 26: 203–234.

53. Chiang JYL (2009) Bile acids: regulation of synthesis. J Lipid Res 50: 1955–1966.

54. Zhang Y, Csanaky IL, Cheng X, Lehman-McKeever LD, Klaassen CD (2012) Organic anion transporting polypeptide 1a1 null mice are sensitive to cholestatic liver injury. Toxicol Sci 127: 451–462.

55. Mennone A, Soroka CJ, Cai SY, Harry K, Adachi M, et al. (2006) Mrp4 but not Mrp3 is required for the hepatic transport of endogenous glucuronides. J Hepatol 44: 768–773.

56. Riis JL, Johansen C, Gesser B, Moller K, Larsen CG, et al. (2004) Lithocholic acid acetate, a bile acid derivative. J Lipid Res 45: 2340–2347.

57. Matsubara T, Yoshinari K, Aoyama K, Sugawara M, Sekiya Y, et al. (2008) Role of vitamin D receptor in the lithocholic acid-mediated CYP3A induction in vitro and in vivo. Drug Metab Dispos 36: 2058–2063.

58. Soroka CJ, Mennone A, Hagey LR, Ballatori N, Boyer JL (2010) Mouse organic anion transporting polypeptide 1a1 null mice have an impaired cytoprotective response in obstructive cholestasis. Hepatology 51: 181–190.

59. Hartmann G, Cheung AKY, Piquette-Miller M (2002) Inflammatory cytokines, solute transporter activity and post-translational modification. Int J Biochem Cell Biol 42: 329–336.

60. Sun J, Kong J, Duan Y, Szeto FL, Liao A, et al. (2006) Increased NF-κB activity by increasing IκBα levels. Nephrol Dial Transplant 21: 889–897.

61. Adachi R, Honma Y, Masuno H, Kawana K, Shimomura I, et al. (2005) Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. J Hepatol 44: 768–773.

62. Ishizawa M, Matsunawa M, Adachi R, Uno S, Ikeda K, et al. (2008) Lithocholic acid derivatives act as selective vitamin D receptor modulators without inducing hypercalcemia. J Lipid Res 49: 763–772.

63. Libermann TA, Baltimore D (1990) Activation of interleukin-6 gene-expression through the NF-κB transcription factor. Mol Cell Biol 10: 2327–2334.

64. Gascon-Barre M, Demers C, Mirshahi A, Neron S, Zalzal S, et al. (2003) The structure of the murine Il-6 gene – high degree conservation of potential regulatory sequences between mouse and human. J Immunol 172: 17701–17709.

65. Libermann TA, Baltimore D (1990) Activation of interleukin-6 gene expression by inflammatory lymphokines. Mol Cell Biol 10: 561–568.

66. Fujihara M, Watanabe T, Okamoto S, Yamamoto K (1990) Involvement of a NF-κB-like transcription factor in the activation of the interleukin-1 gene by inflammatory lymphokines. Mol Cell Biol 10: 561–568.

67. Adachi R, Honma Y, Masuno H, Kawana K, Shimomura I, et al. (2005) In vivo and in vitro and in vivo. Drug Metab Dispos 36: 2058–2063.

68. Sun J, Kong J, Duan Y, Szeto FL, Liao A, et al. (2006) Increased NF-κB activity by increasing IκBα levels. Nephrol Dial Transplant 21: 889–897.

69. Froicu M, Cantorna MT (2007) Vitamin D receptor deletion leads to reduced level of IκBα protein through protein translation, protein-protein interaction, and post-translational modification. Int J Biochem Cell Biol 42: 329–336.

70. Adachi R, Honma Y, Masuno H, Kawana K, Shimomura I, et al. (2005) Selective activation of vitamin D receptor by lithocholic acid acetate, a bile acid derivative. J Lipid Res 46: 46–57.

71. Ishizawa M, Matsunawa M, Adachi R, Uno S, Ikeda K, et al. (2008) Lithocholic acid derivatives act as selective vitamin D receptor modulators without inducing hypercalcemia. J Lipid Res 49: 763–772.

72. Froicu M, Cantorna MT (2007) Vitamin D receptor deletion leads to reduced level of IκBα protein through protein translation, protein-protein interaction, and post-translational modification. Int J Biochem Cell Biol 42: 329–336.

73. Adachi R, Honma Y, Masuno H, Kawana K, Shimomura I, et al. (2005) Selective activation of vitamin D receptor by lithocholic acid acetate, a bile acid derivative. J Lipid Res 46: 46–57.

74. Froicu M, Cantorna MT (2007) Vitamin D receptor deletion leads to reduced level of IκBα protein through protein translation, protein-protein interaction, and post-translational modification. Int J Biochem Cell Biol 42: 329–336.

75. Adachi R, Honma Y, Masuno H, Kawana K, Shimomura I, et al. (2005) Selective activation of vitamin D receptor by lithocholic acid acetate, a bile acid derivative. J Lipid Res 46: 46–57.

76. Froicu M, Cantorna MT (2007) Vitamin D receptor deletion leads to reduced level of IκBα protein through protein translation, protein-protein interaction, and post-translational modification. Int J Biochem Cell Biol 42: 329–336.

77. Adachi R, Honma Y, Masuno H, Kawana K, Shimomura I, et al. (2005) Selective activation of vitamin D receptor by lithocholic acid acetate, a bile acid derivative. J Lipid Res 46: 46–57.

78. Froicu M, Cantorna MT (2007) Vitamin D receptor deletion leads to reduced level of IκBα protein through protein translation, protein-protein interaction, and post-translational modification. Int J Biochem Cell Biol 42: 329–336.

79. Adachi R, Honma Y, Masuno H, Kawana K, Shimomura I, et al. (2005) Selective activation of vitamin D receptor by lithocholic acid acetate, a bile acid derivative. J Lipid Res 46: 46–57.

80. Froicu M, Cantorna MT (2007) Vitamin D receptor deletion leads to reduced level of IκBα protein through protein translation, protein-protein interaction, and post-translational modification. Int J Biochem Cell Biol 42: 329–336.